Drilldown: Medicines
Medicines > onset 
:
Days or
Inhaled: bronchial effect 1-2 weeks; oral GI effect 1-2 weeks or
LDL lowering at 2 weeks, max by 4 weeks
:
Days or
Inhaled: bronchial effect 1-2 weeks; oral GI effect 1-2 weeks or
LDL lowering at 2 weeks, max by 4 weeks Use the filters below to narrow your results.
generic:
brand:
classes:
[[:Category:Antibacterials|Antibacterial]] (1) ·
[[:Category:Antifungals|Antifungal (imidazole)]] (1) ·
[[:Category:Corticosteroids|Corticosteroid]] (1) ·
[[:Category:Glucocorticoids|Glucocorticoid]] (1) ·
[[:Category:Inhaled_corticosteroids|Inhaled corticosteroid (ICS)]] (1) ·
[[:Category:Lipid-lowering_agents|Lipid-lowering agent]] (3) ·
[[:Category:Statins|Statin]] (3) ·
[[:Category:Topical_antibiotics|Topical antibiotic]] (1) ·
[[:Category:Topical_antifungals|Topical antifungal]] (1)
mechanism:
None (4) ·
'"`UNIQ--vote-000003D1-QINU`"' SLCO1B1 polymorphism affects exposure but is most clinically actionable for simvastatin'"`UNIQ--ref-000003D2-QINU`"'. (1) ·
'"`UNIQ--vote-000009FD-QINU`"' Active against gram-positive cocci including MRSA; the unique target underlies the absence of cross-resistance with other antibiotic classes. High-level resistance (plasmid-mediated mupA) is rising and limits prolonged or repeated use'"`UNIQ--ref-000009FE-QINU`"'. (1)
uses:
'"`UNIQ--vote-00000178-QINU`"', '"`UNIQ--vote-00000179-QINU`"' (1) ·
'"`UNIQ--vote-000003D3-QINU`"', '"`UNIQ--vote-000003D4-QINU`"' (1) ·
'"`UNIQ--vote-00000805-QINU`"', '"`UNIQ--vote-00000806-QINU`"' (1) ·
'"`UNIQ--vote-0000099F-QINU`"', '"`UNIQ--vote-000009A0-QINU`"', '"`UNIQ--vote-000009A1-QINU`"', '"`UNIQ--vote-000009A2-QINU`"', '"`UNIQ--vote-000009A3-QINU`"', '"`UNIQ--vote-000009A4-QINU`"' (1) ·
'"`UNIQ--vote-000009FF-QINU`"', '"`UNIQ--vote-00000A00-QINU`"', '"`UNIQ--vote-00000A01-QINU`"' (1) ·
'"`UNIQ--vote-00000F40-QINU`"', '"`UNIQ--vote-00000F41-QINU`"', '"`UNIQ--vote-00000F42-QINU`"', '"`UNIQ--vote-00000F43-QINU`"', '"`UNIQ--vote-00000F44-QINU`"' (1)
starting dose:
10-20 mg PO once daily in the evening (40 mg starting allowed for high CV risk) (1) ·
20 mg PO once daily with the evening meal; titrate to 40-80 mg/d (1) ·
40 mg PO once daily (10-20 mg in elderly, hepatic impairment, or strong drug interactions) (1) ·
ICS Pulmicort Flexhaler 180-360 mcg BID; intranasal Rhinocort 64 mcg/spray, 1-2 sprays/nostril daily; Entocort EC 9 mg PO daily for active Crohn's; Symbicort 80/4.5 or 160/4.5 mcg, 2 puffs BID (1) ·
Topical: 1% cream BID × 2-4 weeks; vaginal: 1% or 2% cream nightly × 7 days, or 100/200/500 mg vaginal tablet single or 3-day regimens; troche: 10 mg PO five times daily × 2 weeks for thrush (1) ·
Topical: apply small amount to affected area TID × 5-10 days; nasal: apply half the contents of a single-use tube into each nostril BID × 5 days (1)
preparations:
1% topical cream, lotion, solution; 1%, 2% vaginal cream; 100, 200, 500 mg vaginal tablets; 10 mg oral troches; combination with betamethasone (Lotrisone, Rx) (1) ·
10 mg, 20 mg, 40 mg, 80 mg tablets (1) ·
10, 20, 40 mg tablets; 20, 40, 60 mg ER tablets (1) ·
2% ointment; 2% cream; 2% nasal ointment (Bactroban Nasal) (1) ·
5, 10, 20, 40, 80 mg tablets; 4 mg/mL oral suspension (1) ·
Pulmicort Flexhaler DPI 90, 180 mcg/dose; Pulmicort Respules 0.25, 0.5, 1 mg/2 mL nebulized; Rhinocort intranasal 32 mcg/spray; Entocort EC 3 mg capsules; Uceris 9 mg ER tablets and rectal foam (1)
fda max:
40 mg/d standard; 80 mg/d restricted to patients tolerating 80 mg for ≥12 months without myopathy (post-SEARCH 2011 FDA restriction) (1) ·
80 mg/d (1) ·
80 mg/d (40 mg/d if combined with diltiazem, verapamil, danazol; lower limits with various interactions) (1) ·
ICS ~1280 mcg/d; intranasal 256 mcg/d; Entocort 9 mg/d standard (1) ·
Limit topical to 10-day courses to reduce resistance pressure (1) ·
Topical: BID; troche: 5×/day (1)
routes:
onset: (Click arrow to add another value)
duration:
halflife:
Not meaningfully described (minimal systemic absorption from topical use)'"`UNIQ--ref-00000F45-QINU`"' (1) ·
Not meaningfully described for topical use'"`UNIQ--ref-00000A02-QINU`"' (1) ·
~2 hours (parent and active β-hydroxy acid metabolite); pharmacodynamic effect lasts 24 hours via target turnover'"`UNIQ--ref-0000017A-QINU`"' (1) ·
~2-3 hours (parent); pharmacodynamic effect 24 hours via target turnover'"`UNIQ--ref-000003D5-QINU`"' (1) ·
~2-3.6 hours (plasma)'"`UNIQ--ref-000009A5-QINU`"' (1) ·
~2-4 hours (parent and active β-hydroxy acid metabolite); pharmacodynamic effect 24 hours via target turnover'"`UNIQ--ref-00000807-QINU`"' (1)
bioavailability:
<5% (extensive hepatic first-pass; food enhances absorption of IR, hence the evening-meal dosing)'"`UNIQ--ref-00000808-QINU`"' (1) ·
<5% (extensive hepatic first-pass; statin pharmacology is hepatocellular, not systemic)'"`UNIQ--ref-0000017B-QINU`"' (1) ·
Topical: minimal systemic; troche: ~3% systemic'"`UNIQ--ref-00000F46-QINU`"' (1) ·
Topical; minimal systemic absorption'"`UNIQ--ref-00000A03-QINU`"' (1) ·
~17% (oral; food slightly reduces absorption)'"`UNIQ--ref-000003D6-QINU`"' (1) ·
~6-13% inhaled lung deposition; ~10% oral (Entocort EC; extensive first-pass via CYP3A4 — this is the basis of the favorable hepatic-targeted local-effect profile in IBD)'"`UNIQ--ref-000009A6-QINU`"' (1)
pregnancy:
Generally considered safe; minimal systemic exposure.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Long the preferred ICS in pregnancy (Pulmicort) due to the most pregnancy data among the class.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Previously Category X; FDA removed the blanket statin contraindication in pregnancy in 2021.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (3) ·
Topical and vaginal generally considered safe; widely used.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 6 results in range #1 to #6.